ArriVent BioPharma Enters Exclusive License with Lepu Biopharma for MRG007, an Antibody Drug Conjugate for the treatment of Gastrointestinal Cancers
January 21, 2025 19:00 ET | Source: ArriVent BioPharma, Inc. Exclusive global…
Adagene to Announce Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA (pembrolizumab) in Colorectal Cancer at ASCO Gastrointestinal Cancers Symposium
January 21, 2025 17:00 ET | Source: Adagene Inc. SAN DIEGO and…